ID | 114924 |
Title Alternative | LPS-CXCL10 Predicts Responses to Bortezomib in Myeloma Patients
|
Author |
Watanabe, Takashi
National Cancer Center Hospital|Komaki City Hospital
Mitsuhashi, Masato
Hitachi Chemical Research Center
Sagawa, Morihiko
Saitama Medical University
Ri, Masaki
Nagoya City University
Suzuki, Kenshi
Japanese Red Cross Medical Center
Abe, Masahiro
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Ohmachi, Ken
Tokai University
Nakagawa, Yasunori
Japanese Red Cross Medical Center
Nakamura, Shingen
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Chosa, Mizuki
National Cancer Center Hospital
Iida, Shinsuke
Nagoya City University
Kizaki, Masahiro
Saitama Medical University
|
Content Type |
Journal Article
|
Description | To identify predictive biomarkers for clinical responses to bortezomib treatment, 0.06 mL of each whole blood without any cell separation procedures was stimulated ex vivo using five agents, and eight mRNAs were quantified. In six centers, heparinized peripheral blood was prospectively obtained from 80 previously treated or untreated, symptomatic multiple myeloma (MM) patients with measurable levels of M-proteins. The blood sample was procured prior to treatment as well as 2-3 days and 1-3 weeks after the first dose of bortezomib, which was intravenously administered biweekly or weekly, during the first cycle. Six stimulant-mRNA combinations; that is, lipopolysaccharide (LPS)-granulocyte-macrophage colony-stimulating factor (GM-CSF), LPS-CXCL chemokine 10 (CXCL10), LPS-CCL chemokine 4 (CCL4), phytohemagglutinin-CCL4, zymosan A (ZA)-GMCSF and ZA-CCL4 showed significantly higher induction in the complete and very good partial response group than in the stable and progressive disease group, as determined by both parametric (t-test) and non-parametric (unpaired Mann-Whitney test) tests. Moreover, LPS-induced CXCL10 mRNA expression was significantly suppressed 2-3 days after the first dose of bortezomib in all patients, as determined by both parametric (t-test) and non-parametric (paired Wilcoxon test) tests, whereas the complete and very good partial response group showed sustained suppression 1-3 weeks after the first dose. Thus, pretreatment LPS-CXCL10 mRNA and/or the six combinations may serve as potential biomarkers for the response to bortezomib treatment in MM patients.
|
Journal Title |
PLOS ONE
|
ISSN | 19326203
|
Publisher | PLOS
|
Volume | 10
|
Issue | 6
|
Start Page | e0128662
|
Published Date | 2015-06-26
|
Rights | © 2015 Watanabe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
|